Jan. 8 at 5:11 PM
$CMPS Let me explain what happened yesterday.
Our current price movement was already climbing up due to ONE indication = Treatment Resistant Depression, or TRD, because our LAST results, topline were: EXCELLENT=IT WORKS. Phase 3 comp006 topline=DUE.
We now have ANOTHER Indication / ALLOWED TREATMENT with the SAME MOLECULE: comp360. NOW: comp360 (
$CMP 's proprietary pure distilled psilocybin in pill powder form-extremely hard to do, which gives us our IP value over unreliable natural 'mushroom dose', + treatment ) will be able to treat, with FDA greenlight ( basically in the bag)
PTSD & TRD =comp360
With PTSD Indication approval yesterday, ( THIS IS BESIDES THE Phase 3 comp006 PENDING TRD topline results for dual dose & long term effects, how well the effects last, Data ) . With Yesterday's anouncement, the FDA LET
$CMPS SKIP*, Phase 1, Phase 2 standalone for PTSD indication, the safety data from prior CMPS studies was so compelling, the FDA decided to
$CMPS an accelerated Phase 2b/3
